Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Guess they haven't eaten through the 400K yet. Hope this gets better soon. What catalyst are we waiting for?
Even though it seems obvious by now what will happen. Does anyone know when we officially find out the outcome of the vote?
Maybe you missed this too.
As of March 31, 2015, the company had cash and cash equivalents of $5,012,605 vs $5,525,094 at March 31, 2014. With a burn rate of roughly $1.5M per quarter, the company has sufficient cash to last until early 2016.
Maybe you missed this.
the Federal Government is funding six of the nine current trials.
Do you or anyone else know what the current OS is? Thanks
What phase is the diabetes trial at? Thanks.
Thank you very much! Going to keep my eye on this one.
Thank you. Any idea how long the trial will last?
Just found this stock. Doing my DD. Something I can't find is when is the phase 3 anticipated to start? Thanks!
Carter Ward said this on the CC:
"Elite will earn manufacturing fees and profit splits based on sales of the product. We expect that this will impact revenues beginning in fiscal 2017 when the product is scheduled for launch".
So product launch is scheduled for fiscal 2017. End of story. Longs continue to wait patiently. All others trade accordingly. Plenty of time here to get in or out IMO. GLTM
Some light reading while we pass the time.
Despite high-profile efforts to implement abuse-deterrent labels and properties on brand-name opioids, advisory company Avalere Health’s latest research notes a key blind spot in the efforts — accessibility. In particular, the research shows that Medicare Part D plans cover generic opioids that lack abuse-deterrent features at a higher rate than it covers branded opioids.
“While there has been significant attention on the development and approval of new abuse-deterrent drug products, there has been noticeably less consideration of access to such products,” Avalere CEO Dan Mendelson said.
Particularly with regard to oxycodone hydrochloride, the brand-name OxyContin received approval from the Food and Drug Administration in 2013 for abuse-deterrent labeling, but since 2012, Part D plan coverage for it has dropped from 61% to 46%. On the other hand, every Part D plan covers generic oxycodone hydrochloride. As a result, seniors have less access to safer opioids.
“While prescription opioid abuse continues to be a priority for public health experts and lawmakers, coverage for these products by Part D plans is limited and plans are increasingly favoring lower-cost generic products on their formularies,” Avalere SVP Caroline Pearson said. “Policymakers seeking to limit opioid abuse will have to balance the desire for greater access to abuse-deterrent opioids with the increased costs of such medications to public programs and private payers.”
Thanks for posting this! I love going back and reading older info knowing where we're at today. He was excited about K's potential at the 4th cohort and here we are at the 11th maybe 12th!
Ok thanks. Guess it was something specific. I answered the other poster too early. Will keep an eye on it.
Thanks again.
Thank you. I thought the poster was referencing something specific happening tomorrow. When I couldn't find it I figured I'd ask. Thanks again.
New here. What happens tomorrow? Thanks.
Nice call. Where's it headed next?
So do you think this is a scam with no potential? Or one of those "real" company's who sells shares for a living. They made a couple of deals recently so I'm inclined to believe they are an actual company trying to make it happen. I'm only vaguely familiar with your reference to an older company. Care to expand? Thanks.
How much do you think they'll get bought for?
Has this been halted? No trades so far.
I wonder if the release of news after the market closes is because of up list announcement. Guess we'll see. Either way still happy with the long term outlook.
About Ovarian Cancer:
Ovarian cancer is the most lethal of the gynecologic cancers, representing the ninth most common cancer among women and the fifth leading cause of cancer related death among women. It most commonly occurs in postmenopausal women. Ninety per cent of ovarian cancers are derived from the ovarian surface epithelium and these neoplasm are classified into serous, mucinous, endometrioid, clear-cell and transitional-cell types. The molecular pathology of ovarian carcinomas is heterogeneous and involves various putative precursor lesions and multiple pathways of development. The most common subtype, high-grade serous carcinoma, is characterized by p53 mutations, and BRCA1 and/or BRCA2 dysfunction.
It would be awesome if K could cure it. A lot of wives, mothers and daughters would be saved! Happy to invest money in something that could save lives. Excited about the progression. So far so good...
Krishna Menon, Chief Scientific Officer at Cellceutix. "We are pleased to once again present at ASCO. We believe the interest in Cellceutix has never been greater."
Curing Cancers, killing superbugs and stopping psoriasis are all in CTIX's pipeline! How long till partnerships are announced?
Looks like Menon is excited about the presentation. Btw how many Pr's does Menon do? Few and far between.
"The Poster at ASCO is a meaningful advancement in the progression of Kevetrin as we look towards Phase 2 trials to further evaluate our novel compound's effect on p53 in solid and liquid tumors," commented Krishna Menon, Chief Scientific Officer at Cellceutix. "We are pleased to once again present at ASCO. We believe the interest in Cellceutix has never been greater."
IMO - Menon is the true genius at this company. If he's psyched I am psyched!
Just curious who was the other company in the article mention along side of CTIX. TIA
How soon till someone starts the guess the new company name game. I think it'll just be "Sunworks".
Closing bell Thursday.
I think that's the 10 milly job.
Any longs still here following this stock? Not a lot of information to be found about the company. Anybody still believe and why? Thanks for taking the time to share if you do.
Thanks. Hope that's enough time for them to start to turn it around. Guess we'll see. Tempted but Still on the sidelines waiting for proof. GL
How long do they have to make that happen?
Friday release. Weekend review. Monday CC. What a way to make it official. OTC rear view mirror. We shall see...
Thought this was very relevant to the massive potential CTIX has. The pharmaceutical world will be chasing to catch up to them.
Denise Roland
May 13, 2015 7:04 p.m. ET
LONDON—A multibillion-dollar investment into the global pharmaceuticals industry is needed to ward off the threat of drug-resistant “superbugs,” according to Jim O’Neill, the economist leading a review into antimicrobial resistance for the U.K. government.
Mr. O’Neill, best known for coining the “BRIC” acronym for Brazil, Russia, India and China while at Goldman Sachs, estimated that as much as $37 billion is needed over the next 10 years to spur the industry to develop innovative antibiotics, since there is little market incentive to do so.
The economist said he was “open” to different sources of funding but said that some will “almost certainly come from the global taxpayer.”
Mr. O’Neill added that this sum was “modest” in comparison with the economic cost of ignoring the problem. In an earlier report, he estimated that antimicrobial resistance, or AMR, would kill 300 million people prematurely in the next 35 years if unaddressed, leaving global gross domestic product 2% to 3.5% short of what it otherwise would have been by 2050. That would mean $60 trillion to $100 trillion in lost economic output over that 35-year span.
Pharmaceutical companies largely retreated from antibiotic research during the 1990s, due to a high degree of uncertainty on the eventual market size for any novel drugs. A plentiful supply of older and cheaper antibiotics means that a novel product will be used only after other treatments have failed.
This should be a sticky! The Leo haters have little historical knowledge. Thank you for edumacaten dem foos
Thank you for taking the time to answer my question. Appreciate everyone's perspective. I think you're right to be bullish. there could be a great turn around story taking place here. Going to keep watching it unfold. Seems like it's going to take a little more time though. Opportunity to wait for a nice entry price IMO. Thanks again.
Hello board. Been watching this stock for a while trying to find a bottom. With the CEO saying at the last CC,
"East Coast weather which is certainly impacting our first quarter 2015 revenue results". Do you guys think we have further to fall? Or do you think since he said it and lowered expectations it won't have a huge impact. TIA.
I noticed some of the glass half empty posters are now seeing the glass half full. Hope this signals the bottom.
I think up listing to the NASDAQ will bring the CTIX pipeline the attention it deserves. Right now it's easy to not be on the radar screen of analysts. Not many analysts or investors take companies on the pink sheets seriously. Just my opinion. Good luck to most.
Everyone knows Leo doesn't play golf. I heard he likes to bowl. He's been seen slaying pins down at the Boca Bowl-a-rama with his bowling buddies.
I guess the 4th was not with us today. Unless you're buying. Then the 4th was strong with you. What a bargain IMO. If I only had more funds. I really believed that with the rumor of Leo being such a huge Stars Wars fan (heard he was going to name his third kid Jarjar Ehrlich;) that we didn't get the uplist news. Oh well. As long as it happens before May is over Its all good. I really believe CTIX is not mentioned in articles related to antibiotics because their looked at as a stinky pinky. The NASDAQ gives an air of legitimacy that can't be easily ignored and is more likely to get picked up on writers radar screen. IMO it's Just a matter of time before the world knows about this little company that could. Good luck to the Best board on Ihub.
No it doesn't. If you were here last year you would have seen that the same conference did very little to effect the stock price. In fact I think it went down after too. If you are a long All that matters is the Science. We know if the science is great than the Stock price will catch up eventually. IMO.